Youichi Shinozaki

Dr. Youichi Shinozaki


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2007 in Nature
Verified
Journal Article
Closed access
PDF file
SKSchuichi Koizumi
Schuichi Koizumi
YSYukari Shigemoto-Mogami
Yukari Shigemoto-Mogami
KNKaoru Nasu-Tada
Kaoru Nasu-Tada
YSYouichi Shinozaki
Youichi Shinozaki
KOKeiko Ohsawa
Keiko Ohsawa
KIKazuhide Inoue
Kazuhide Inoue

1 May 2017 in Cell Reports
Verified
Journal Article
Open access
YSYouichi Shinozaki
Youichi Shinozaki
KSKeisuke Shibata
Keisuke Shibata
KYKeitaro Yoshida
Keitaro Yoshida
ESEiji Shigetomi
Eiji Shigetomi
CGChristian Gachet
Christian Gachet
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi
Microglia and astrocytes become reactive following traumatic brain injury (TBI). However, the coordination of this reactivity and its relation to pathophysiology are unclear. Here, we show that microglia transform astrocytes into a neuroprotective phenotype via downregulation of the P2Y1 purinergic receptor. TBI initially caused microglial activation in the injury core, followed by reactive astrogliosis in the peri-injured region and formation of a neuroprotective astrocyte scar. Equivalent changes to astrocytes were observed in vitro after injury. This change in astrocyte phenotype resulted from P2Y1 receptor downregulation, mediated by microglia-derived cytokines. In mice, astrocyte-specific P2Y1 receptor overexpression (Astro-P2Y1OE) counteracted scar formation, while astrocyte-specific P2Y1 receptor knockdown (Astro-P2Y1KD) facilitated scar formation, suggesting critical roles of P2Y1 receptors in the transformation. Astro-P2Y1OE and Astro-P2Y1KD mice showed increased and reduced neuronal damage, respectively. Altogether, our findings indicate that microglia-astrocyte interaction, involving a purinergic signal, is essential for the formation of neuroprotective astrocytes.

11 April 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SKSun Kwang Kim
Sun Kwang Kim
HHHideaki Hayashi
Hideaki Hayashi
TITatsuya Ishikawa
Tatsuya Ishikawa
KSKeisuke Shibata
Keisuke Shibata
ESEiji Shigetomi
Eiji Shigetomi
Junichi NabekuraJunichi Nabekura
Junichi Nabekura
Long-term treatments to ameliorate peripheral neuropathic pain that includes mechanical allodynia are limited. While glial activation and altered nociceptive transmission within the spinal cord are associated with the pathogenesis of mechanical allodynia, changes in cortical circuits also accompany peripheral nerve injury and may represent additional therapeutic targets. Dendritic spine plasticity in the S1 cortex appears within days following nerve injury; however, the underlying cellular mechanisms of this plasticity and whether it has a causal relationship to allodynia remain unsolved. Furthermore, it is not known whether glial activation occurs within the S1 cortex following injury or whether it contributes to this S1 synaptic plasticity. Using in vivo 2-photon imaging with genetic and pharmacological manipulations of murine models, we have shown that sciatic nerve ligation induces a re-emergence of immature metabotropic glutamate receptor 5 (mGluR5) signaling in S1 astroglia, which elicits spontaneous somatic Ca2+ transients, synaptogenic thrombospondin 1 (TSP-1) release, and synapse formation. This S1 astrocyte reactivation was evident only during the first week after injury and correlated with the temporal changes in S1 extracellular glutamate levels and dendritic spine turnover. Blocking the astrocytic mGluR5-signaling pathway suppressed mechanical allodynia, while activating this pathway in the absence of any peripheral injury induced long-lasting (>1 month) allodynia. We conclude that reawakened astrocytes are a key trigger for S1 circuit rewiring and that this contributes to neuropathic mechanical allodynia.

5 July 2013 in Glia
Verified
Journal Article
Closed access
PDF file
YIYoshio Imura
Yoshio Imura
YMYosuke Morizawa
Yosuke Morizawa
RKRyohei Komatsu
Ryohei Komatsu
KSKeisuke Shibata
Keisuke Shibata
YSYouichi Shinozaki
Youichi Shinozaki
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi

10 May 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
FSFumikazu Sano
Fumikazu Sano
ESEiji Shigetomi
Eiji Shigetomi
YSYouichi Shinozaki
Youichi Shinozaki
HTHaruka Tsuzukiyama
Haruka Tsuzukiyama
KSKozo Saito
Kozo Saito
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi
Extensive activation of glial cells during a latent period has been well documented in various animal models of epilepsy. However, it remains unclear whether activated glial cells contribute to epileptogenesis, i.e., the chronically persistent process leading to epilepsy. Particularly, it is not clear whether interglial communication between different types of glial cells contributes to epileptogenesis, because past literature has mainly focused on one type of glial cell. Here, we show that temporally distinct activation profiles of microglia and astrocytes collaboratively contributed to epileptogenesis in a drug-induced status epilepticus model. We found that reactive microglia appeared first, followed by reactive astrocytes and increased susceptibility to seizures. Reactive astrocytes exhibited larger Ca 2+ signals mediated by IP 3 R2, whereas deletion of this type of Ca 2+ signaling reduced seizure susceptibility after status epilepticus. Immediate, but not late, pharmacological inhibition of microglial activation prevented subsequent reactive astrocytes, aberrant astrocyte Ca 2+ signaling, and the enhanced seizure susceptibility. These findings indicate that the sequential activation of glial cells constituted a cause of epileptogenesis after status epilepticus. Thus, our findings suggest that the therapeutic target to prevent epilepsy after status epilepticus should be shifted from microglia (early phase) to astrocytes (late phase).

1 June 2018 in EBioMedicine
Verified
Journal Article
Open access
MKManao Kinoshita
Manao Kinoshita
YHYuri Hirayama
Yuri Hirayama
KFKayoko Fujishita
Kayoko Fujishita
KSKeisuke Shibata
Keisuke Shibata
YSYouichi Shinozaki
Youichi Shinozaki
Schuichi KoizumiSchuichi Koizumi
Schuichi Koizumi
Although psychotropic drugs act on neurons and glial cells, how glia respond, and whether glial responses are involved in therapeutic effects are poorly understood. Here, we show that fluoxetine (FLX), an anti-depressant, mediates its anti-depressive effect by increasing the gliotransmission of ATP. FLX increased ATP exocytosis via vesicular nucleotide transporter (VNUT). FLX-induced anti-depressive behavior was decreased in astrocyte-selective VNUT-knockout mice or when VNUT was deleted in mice, but it was increased when astrocyte-selective VNUT was overexpressed in mice. This suggests that VNUT-dependent astrocytic ATP exocytosis has a critical role in the therapeutic effect of FLX. Released ATP and its metabolite adenosine act on P2Y11 and adenosine A2b receptors expressed by astrocytes, causing an increase in brain-derived neurotrophic factor in astrocytes. These findings suggest that in addition to neurons, FLX acts on astrocytes and mediates its therapeutic effects by increasing ATP gliotransmission.